by Chloe Sullivan | Sep 15, 2026 | EPO
Background The case concerned Bristol-Myers Squibb’s (BMS) European patent No. 3288980, which was directed to the treatment of PD-L1-positive melanoma by administering nivolumab as a monotherapy. The patent had previously been revoked by the Opposition Division for...
by David Eyre | Sep 8, 2026 | EPO
In these proceedings the European Patent Office (EPO) Technical Boards of Appeal (TBA) revoked a patent owned by Husqvarna AB following an appeal brought by Brokk AB. With regard to assessing amendments for addition of matter under Article 123(2) EPC the TBA were...
by Sean Hutchinson | Sep 4, 2026 | EPO
Background For a long time, the EPO has required applicants to amend the descriptions of their European patent applications to bring these into conformity with the allowed claims before it will grant a European patent. However, in recent years the legal basis for the...
by Luke Pettit | Jul 30, 2026 | US & International
As a reminder, this case addresses how the Hatch-Waxman act “carve-out” provisions (which has led to the emergence of “skinny labels”) interacts with US law on induced patent infringement. This case is the first time the US Supreme Court has had the opportunity to...
by Alyson Lam | Jul 28, 2026 | US & International
On 16–17 June 2026, the Court heard Otsuka’s appeal in Otsuka Pharmaceutical Co Ltd v Sun Pharma ANZ Pty Ltd. The appeal challenges the Full Federal Court’s finding that formulation patents are not eligible for patent term extensions (PTEs). The decision, expected in...
Recent Comments